Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 17/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5677606 | 0.77 | ALDH1A1 (0.48) | ALDH1A1 | |
| SCHEMBL5148657 | 0.75 | HSD11B1 (0.46) | HSD11B1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL5680329 | 0.70 | HSD11B1 (0.36) | HSD11B1MEN1KMT2A | |
| SCHEMBL18135490 | 0.69 | HSD11B1 (0.55) | HSD11B1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL24380154 | 0.68 | HSD11B1 (0.46) | HSD11B1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL2960096 | 0.67 | HSD11B1 (0.53) | HSD11B1MEN1KMT2APOLB | |
| SCHEMBL16566362 | 0.67 | HSD11B1 (0.49) | HSD11B1MEN1KMT2APOLB | |
| SCHEMBL14459065 | 0.64 | HSD11B1 (0.56) | HSD11B1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL7865257 | 0.64 | HSD11B1 (0.56) | HSD11B1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL15483369 | 0.64 | HSD11B1 (0.41) | HSD11B1MEN1KMT2APOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497268-A4 | NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2006-01-18 | — | — | EP | disclosed |
| EP-1497268-A2 | NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20030203915-A1 | Nitric oxide donors, compositions and methods of use related applications | NICOX S.A. (FR) | 2003-10-30 | — | — | US | disclosed |
| WO-2003086282-A2 | NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203915-A1 | Nitric oxide donors, compositions and methods of use related applications | NOS1, NOS2, NOS3 | HSD11B1 1196/4885MEN1 3465/4885KMT2A 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.